Literature DB >> 16421682

Effect of propofol on ropivacaine metabolism in human liver microsomes.

Yoshiko Osaka1, Shinichi Inomata, Einosuke Tanaka, Takako Nakamura, Katsuya Honda, Masayuki Miyabe, Hidenori Toyooka, Makoto Tanaka.   

Abstract

A combination of the general anesthetic propofol and epidural anesthesia with a local anesthetic is widely used. The metabolism of ropivacaine and that of lidocaine are mediated by similar P450 isoforms. Previously, propofol was found to inhibit the metabolism of lidocaine in vitro. Here we investigated whether propofol inhibits the metabolism of ropivacaine using human liver microsomes in vitro. Ropivacaine (6.0 micromol.l(-1)) as the substrate and propofol (1-100 micromol.l(-1)) were reacted together using human microsomes. The concentrations of ropivacaine and its major metabolite 2',6'-pipecoloxylidide (PPX) were measured using high-performance liquid chromatography. The metabolic activity of ropivacaine was reflected in the production of PPX. The inhibitory effects of propofol on ropivacaine metabolism were observed to be dose-dependent. The IC50 of propofol was 34.9 micromol.l(-1). Propofol shows a competitive inhibitory effect on the metabolism of ropivacaine (i.e., PPX production mediated by CYP3A4) in human CYP systems in vitro.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16421682     DOI: 10.1007/s00540-005-0358-5

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  22 in total

Review 1.  Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics.

Authors:  M Schulz; A Schmoldt
Journal:  Pharmazie       Date:  2003-07       Impact factor: 1.267

Review 2.  Propofol: a new intravenous anesthetic.

Authors:  P S Sebel; J D Lowdon
Journal:  Anesthesiology       Date:  1989-08       Impact factor: 7.892

3.  Effect of clarithromycin and itraconazole on the pharmacokinetics of ropivacaine.

Authors:  M J Jokinen; J Ahonen; P J Neuvonen; K T Olkkola
Journal:  Pharmacol Toxicol       Date:  2001-04

4.  Involvement of human liver cytochrome P4502B6 in the metabolism of propofol.

Authors:  Y Oda; N Hamaoka; T Hiroi; S Imaoka; I Hase; K Tanaka; Y Funae; T Ishizaki; A Asada
Journal:  Br J Clin Pharmacol       Date:  2001-03       Impact factor: 4.335

5.  Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes.

Authors:  M H Court; S X Duan; L M Hesse; K Venkatakrishnan; D J Greenblatt
Journal:  Anesthesiology       Date:  2001-01       Impact factor: 7.892

6.  The effect of erythromycin, fluvoxamine, and their combination on the pharmacokinetics of ropivacaine.

Authors:  M J Jokinen; J Ahonen; P J Neuvonen; K T Olkkola
Journal:  Anesth Analg       Date:  2000-11       Impact factor: 5.108

7.  Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study.

Authors:  N Hamaoka; Y Oda; I Hase; K Mizutani; T Nakamoto; T Ishizaki; A Asada
Journal:  Clin Pharmacol Ther       Date:  1999-08       Impact factor: 6.875

8.  Effect of ciprofloxacin on the pharmacokinetics of ropivacaine.

Authors:  Mika J Jokinen; Klaus T Olkkola; Jouni Ahonen; Pertti J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  2003-01-29       Impact factor: 2.953

9.  Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes.

Authors:  Corinne Lejus; Alain Fautrel; Yannick Mallédant; André Guillouzo
Journal:  Biochem Pharmacol       Date:  2002-10-01       Impact factor: 5.858

10.  Human cytochrome P450 mono-oxygenase system is suppressed by propofol.

Authors:  T L Chen; T H Ueng; S H Chen; P H Lee; S Z Fan; C C Liu
Journal:  Br J Anaesth       Date:  1995-05       Impact factor: 9.166

View more
  2 in total

1.  Ring-oxidative biotransformation and drug interactions of propofol in the livers of rats.

Authors:  Yu-Ting Tai; Yi-Ling Lin; Chia-Chen Chang; Yih-Giun Cherng; Ming-Jaw Don; Ruei-Ming Chen
Journal:  Biomed Res Int       Date:  2015-02-01       Impact factor: 3.411

2.  Propofol protects human cardiac cells against chemical hypoxiainduced injury by regulating the JNK signaling pathways.

Authors:  Liu Han; Qiang Zhuo; Ying Zhou; Yanning Qian
Journal:  Exp Ther Med       Date:  2020-01-08       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.